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Abstract
Background
Validation of previously identified candidate biomarkers and identification of additional can-
didate gene expression profiles to facilitate diagnosis of tuberculosis (TB) disease and moni-
toring treatment responses in the Ethiopian context is vital for improving TB control in the
future.
Methods
Expression levels of 105 immune-related genes were determined in the blood of 80 HIV-
negative study participants composed of 40 active TB cases, 20 latent TB infected individu-
als with positive tuberculin skin test (TST+), and 20 healthy controls with no Mycobacterium
tuberculosis (Mtb) infection (TST-), using focused gene expression profiling by dual-color
Reverse-Transcription Multiplex Ligation-dependent Probe Amplification assay. Gene
expression levels were also measured six months after anti-TB treatment (ATT) and follow-
up in 38 TB patients.
Results
The expression of 15 host genes in TB patients could accurately discriminate between TB
cases versus both TST+ and TST- controls at baseline and thus holds promise as biomarker
signature to classify active TB disease versus latent TB infection in an Ethiopian setting.
Interestingly, the expression levels of most genes that markedly discriminated between TB
cases versus TST+ or TST- controls did not normalize following completion of ATT therapy
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at 6 months (except for PTPRCv1, FCGR1A, GZMB, CASP8 and GNLY) but had only fully
normalized at the 18 months follow-up time point. Of note, network analysis comparing TB-
associated host genes identified in the current HIV-negative TB cohort to TB-associated
genes identified in our previously published Ethiopian HIV-positive TB cohort, revealed an
over-representation of pattern recognition receptors including TLR2 and TLR4 in the HIV-
positive cohort which was not seen in the HIV-negative cohort. Moreover, using ROC cutoff
� 0.80, FCGR1A was the only marker with classifying potential between TB infection and
TB disease regardless of HIV status.
Conclusions
Our data indicate that complex gene expression signatures are required to measure blood
transcriptomic responses during and after successful ATT to fully diagnose TB disease and
characterise drug-induced relapse-free cure, combining genes which resolve completely
during the 6-months treatment phase of therapy with genes that only fully return to normal
levels during the post-treatment resolution phase.
Background
Tuberculosis (TB) is a leading cause of death [1] and 25% of the 10.0 million incident TB dis-
ease cases globally were reported in Africa during 2017 [2]. WHO recommends developing
effective diagnostic tests and treatments for latent TB infection (LTBI) to achieve a 90% and
80% reduction of the incidence and death rate from Mycobacterium tuberculosis (Mtb) respec-
tively by 2030 [3]. The currently available diagnostic tools (smear microscopy, solid and liquid
sputum culture, Genexpert) have several limitations to detect latent and active TB [4,5,6,7] and
for monitoring TB treatment response [8], and those limitations greatly contribute to the
spread of TB disease.
Because existing immunological methods to diagnose TB infection, such as the tuberculin
skin test (TST) and Interferon-γ release assays (IGRAs), are not able to distinguish between
LTBI and active TB disease [9], it has been suggested that the identification of biomarkers that
can classify clinical stages of TB and monitor TB treatment responses is essential and cost-
effective for improving clinical practice [10]. Changes in gene expression in peripheral blood
due to the interaction between the host immune response and Mtb could potentially be used
as biomarkers to classify the different clinical outcomes of TB exposure and to monitor TB
treatment response. There have been previous studies showing that various stages of Mtb
infection can be distinguished using gene expression profiling in peripheral blood for the diag-
nosis of TB disease and monitoring TB treatment [11,12,13,14,15,16,17,18] in cohorts from
Europe, North and South America, Asia and Africa (South Africa, Malawi and Gambia). For
instance, Wu and colleagues [15] identified 10 genes whose expression differentiated patients
with active TB disease from LTBI individuals in a North American cohort. Kaforou and col-
leagues [16] identified and validated a 44 gene signature that distinguished active tuberculosis
from other diseases in different African cohorts, while Warsinske and his colleagues [17] iden-
tified a 3-gene messenger RNA expression score that distinguished individuals who progressed
to TB cases from non progressors, individuals with TB cases from non TB cases, and individu-
als with slower treatment response during TB therapy in Brazil and South Africa. However,
those host markers may not be applicable in another population, because various studies have
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indicated that diverse genetic backgrounds and environmental factors impact on gene expres-
sion and cytokine profiles in peripheral blood [19,20]. Mihret and colleagues [21] found 9 host
genes, identified from a limited panel of 45 host genes, which discriminated patients with
active TB disease from household contacts in the context of Ethiopia. However, validating
those signatures and identifying additional candidate genes for diagnosing TB disease will be
important. Therefore, in this study we aimed to validate and identify novel candidate host
gene biomarkers that classify active TB disease and that can be used to monitor TB treatment
responses in the context of Ethiopia, using focused gene expression profiling by dual-color
Reverse-Transcription Multiplex Ligation-dependent Probe Amplification (dcRT-MLPA).
Materials and methods
Ethics statement
All study participants provided written, informed consent at enrollment. The study obtained
ethical clearance from the Scientific and Ethics Research Office (Ref: EHNRI 6.13/01), the
Ethiopian Public Health Research Institute, and the London School of Hygiene & Tropical
Medicine Ethics Review Committee (Ref:7174).
Study design and population
An observational cohort study was conducted between April 2007 and January 2011 at three
health facilities (St. Peter Specialized TB Hospital, Akaki and Kality Health Centers), Addis
Ababa, Ethiopia. Study participants were adults of both sexes ranging between 15–65 years of
age. Demographic data of the study participants were collected using a standard questionnaire
at recruitment and follow-up. A total of 80 study participants were enrolled, including 40
active TB cases, 20 latent TB infected individuals (tuberculin skin test positive; TST+), and 20
healthy controls (TST-) and they were all HIV negative. The latent TB and control group (20
TST+ and 20 TST- subjects) had no prior diagnosis of TB and were recruited without any clin-
ical symptoms or signs of illness due to active TB and HIV/AIDS. Possible study participants
who refused HIV testing, were pregnant, had co-morbidity with diabetes mellitus or chronic
bronchitis, were receiving steroid therapy, had received TB treatment (at recruitment or previ-
ously), or who had alcohol or drug abuse that could compromise reliability, were excluded
from the enrollment. All active TB cases confirmed at enrollment were treated according to
the national guideline [22] and followed until the end of anti-tuberculosis treatment (ATT) at
6 months (6M) and additionally at 18 months (18M). Furthermore, they were negative for
Acid Fast Bacilli (AFB) by microscopy and clinically asymptomatic at 6M and 18M.
Diagnostic assessment
The HIV status of study participants was determined using the Determine HIV-½ (Abbott lab-
oratories, Japan) as the screening test, the Capilus HIV-½ (TrinityBiotec, Ireland) as the con-
firmatory test and Unigold HIV-½ recombinant (TrinityBiotec, Ireland) as a tie breaker test
[22]. The CD4 count was determined by flow cytometry using a FACSCalibur Flow cytometer
(Becton Dickinson, San Jos, USA).
Active TB diagnosis was based on both clinical and bacteriological parameters. At least two
sputum smears (“spot-early morning”) were required to be positive by microscopy for Acid
Fast Bacilli (AFB) using the Ziehl-Neelsen staining method [22]. A TST test to detect latent TB
infection was performed at baseline and follow-up visits for all participants except active TB
patients according to the national guidelines [22]. A 0.1ml tuberculin solution (RT23, State
Serum Institute, Copenhagen) was injected intradermally into the dorsal surface of the
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forearm. TST positivity was classified as skin induration diameter�10 mm in HIV-uninfected
individuals [22].
RNA extraction
RNA was extracted from 2.5ml blood collected in Paxgene tubes (PreAnalytiX, Qiagen, Ger-
many) using the Paxgene RNA extraction kit (PreAnalytiX, Qiagen) according to the manufac-
turer’s instructions. Briefly, Paxgene tubes were centrifuged at 4000 rpm for 10 minutes and
the pellet was lysed and resuspended by Resuspension Buffer (Buffer BR1), followed by treat-
ment with proteinase K to remove contaminating proteins. Ethanol-precipitated nucleic acids
were loaded onto a spin column followed by on-column DNA digestion using RNase-free
DNase (Qiagen). Finally, purified RNA was eluted with RNase-free buffer (BR5 buffer) and
quantified using a NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific, Wilming-
ton, USA). RNA samples with 260/280 nm absorbance ratios below 1.70 or above 2.3 were
excluded from further analyses.
Dual-color Reverse-Transcription Multiplex Ligation-dependent Probe
Amplification (dcRT-MLPA)
DcRT-MLPA was performed as described in detail elsewhere [18]. Briefly, for each target-spe-
cific sequence, a specific reverse transcription (RT) primer was designed located immediately
downstream of the left and right-hand half-probe target sequence. Complementary DNA
(cDNA) was generated from RNA using an RT primer mix. Subsequently, MMLV reverse
transcriptase was inactivated by heating at 98˚C for 2 minutes and cDNA was incubated over-
night at 60˚C with a mixture of customized left and right-hand half-probes to hybridize with
the target cDNA. Annealed half-probes were ligated using ligase-65 enzyme and subsequently
amplified by PCR (33 cycles of 30 sec at 95˚C, 30 sec at 58˚C, and 60 sec at 72˚C, followed by 1
cycle of 20 min at 72˚C). Primers and probes were from Sigma-Aldrich Chemie (Zwijndrecht,
The Netherlands) and MLPA reagents from MRC-Holland (Amsterdam, The Netherlands).
PCR amplification products were 1:10 diluted in HiDi formamide-containing 400HD ROX
size standard, denatured at 95 oC for 5 min, cooled on ice and analyzed on an Applied Biosys-
tems 3730 capillary sequencer in GeneScan mode (Base Clear, Leiden, The Netherlands).
Trace data were analyzed using GeneMapper software 5 package (Applied Biosystems). The
areas of each assigned peak (in arbitrary units) were exported for further analysis in Microsoft
Excel spreadsheet software. Data were normalized to GAPDH and signals below the threshold
value for noise cutoff in GeneMapper (log2 transformed peak area 7.64) were assigned the
threshold value for noise cutoff. Finally, the normalized data were log2 transformed for statisti-
cal analysis.
RT primers and half-probes were designed by Leiden University Medical Centre (LUMC,
Leiden, The Netherlands) [18,23] and comprised sequences for 4 housekeeping genes and 105
selected genes to profile the innate and adaptive immune response (S1 Table). Genes associ-
ated with active TB disease or protection against disease, as described in the literature, were
included in the study.
Statistical analysis
The Kolmogorov Smirnov test showed the data were not normally distributed. A non-
parametric Kruskal-Wallis H test was used to compare medians among more than two clinical
groups. A non-parametric two tailed Wilcoxon rank-sum (Mann-Whitney) test was used to
compare two unpaired data sets while a Wilcoxon signed-rank test was used for two paired
data sets., Ingenuity Pathway Analysis (IPA) was used to look the network of those genes that
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discriminate TB cases from controls in HIV positive and HIV negative patients. The statistical
significance level used was P<0.05 and all P values are two-tailed. All data analysis was per-
formed using Inter cooled STATA version 11.0 (College Station, Texas, USA).
Results
Characteristics of the study population
A total of 80 HIV-negative study participants composed of 40 TB cases, 20 TST+ and 20 TST-
were included in this study. Malnutrition (BMI<18.5 kg/m2) was detected in 52% of TB
patients compared to 15% of TST+ and 0% of TST- individuals (Table 1).
Gene expression profiles descriminating active TB from latent infection
Whole blood gene expression levels of TB cases, TST+ and TST- individuals were analyzed by
dcRT-MLPA using probe sets for 105 selected genes to profile innate and adaptive immune
responses (S1 Table). Of the 105 host genes analysed, 54 genes were not differentially
expressed between the three clinical groups (TB cases, TST+ and TST-) and were excluded
from further analysis. Thirty nine genes, including CD19, NCAM1, CD3E, CD4, CD8A, CCR7,
IL7R, PTPRCv1, IL2, GATA3, IL5, IL13, CCL4, CTLA4, GNLY, GZMB, PRF1, CASP8, BCL2,
TNFRSF1A, TNFRSF1B, CD163, CCL5, CCL22, CXCL13, IL12B, TLR9, NLRP1, NLRP2,
NLRP12, NLRP13, TIMP2, AREG, TGFBR2, RAB33A, BPI, TWIST1, SEC14L1, and BLR1, had
significantly lower expression in TB cases compared to TST+ subjects, while 9 genes including
AIRE, CCL2, IL23A, MRC2, NOD2, TLR3, TLR5, FCGR1A and TAGAP were significantly
more highly expressed in TB patients compared to TST+ subjects (Table 2).
Thirty-one host genes including CD19, NCAM1, CD3E, CD4, CD8A, CCR7, IL7R,
PTPRCv1, GATA3, IL5, IL13, CCL4, CTLA4, GNLY, GZMB, PRF1, CASP8, BCL2,
TNFRSF1A, CD163, CCL2, CCL5, TLR9, NLRP1, NLRP2, NLRP12, AREG, RAB13, RAB33A,
SEC14L1 and BLR1 had significantly lower expression in TB patients compared to TST- sub-
jects; while 8 genes including AIRE, TNF, MRC2, NOD2, TLR5, FCGR1A, RAB24 and
TAGAP were significantly more highly expressed in TB cases compared to TST- subjects. All
Table 1. Baseline demographic and clinical characteristics of the study populations.
Characteristics TB cases (n = 40) TST+ (n = 20 TST- (n = 20) P-value
Demographic data
Age, years 27 ± 9.3 23 ± 6.3 22.5 ± 6.0 0.0546
Female, n (%) 17 (42.5) 14 (70) 14 (70) 0.046
Median of BMI, kg/m2 (IQR) 18.4 (16.9–20.0) 21.6 (19.2–23.5) 21.3 (19.5–23.1) 0.0001
Nutritional status
Severe malnutrition, n (%) 6 (15) 0 (0) 0 (0)
Moderate malnutrition, n (%) 4 (10) 0 (0) 0 (0)
Mild malnutrition, n (%) 11 (27.5) 3 (15) 0 (0)
Normal, n (%) 17 (42.5) 14 (70) 18 (90)
Overweight, n (%) 2 (5) 3 (15) 2 (10)
CD4± T cell count
Median CD4+ T cell count (IQR) 426 (292.5–636) 713.5 (573.5–943.5) 821 (693–903) 0.0001
CD4+ T cell count� 200 cells/ μl, n (%) 16 (40) 1 (5) 1 (5) 0.1048
Data indicate medians ± standard deviations unless stated otherwise. BMI cutoff of <18.5 kg/m2 was used to define underweight. A CD4+ T-cell count cutoff of <200
cells/μl was used to define lymphocytopenia. n (%): Number of patients (Percentage of patients); BMI: Body Mass Index. P-values� 0.05 are indicated in bold.
https://doi.org/10.1371/journal.pone.0226137.t001
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Table 2. Gene expression profiles differentiating between study groups at baseline (0M).
Gene Symbol TB cases (n = 40) TST+ (n = 20) TST- (n = 20) TB cases vs TST+
P-value
TB cases vs TST-
P-value
TST+ vs TST-
P-value
Immune cell subset markers
CD19 7.6(7.6–7.6) 7.7(7.6–8.1) 8.2(7.8–8.6) 0.0000 0.0000 0.0424
NCAM1 8.4(7.6–8.7) 9.4(8.8–9.9) 9.3(8.7–9.6) 0.0000 0.0002 0.6456
T cell subset markers
CD3E 12.5(11.3–13.0) 14.2(13.8–14.6) 14.1(13.7–14.3) 0.0000 0.0000 0.3577
CD4 12.0(11.4–12.5) 12.8(12.4–13.3) 12.3(12.1–12.9) 0.0001 0.0137 0.0834
CD8A 12.7(12.3–13.0) 13.0(12.8–13.4) 13.1(12.9–13.2) 0.0021 0.0005 1.0000
CCR7 12.8(12.2–13.4) 14.7(14.1–15.0) 14.2(14.0–14.4) 0.0000 0.0000 0.0620
IL7R 12.1(11.7–13.0) 14.1(13.7–14.5) 14.1(13.8–14.4) 0.0000 0.0000 0.8077
PTPRCv1 10.7(10.2–11.3) 12.1(11.5–12.3) 12.0(11.3–12.2) 0.0000 0.0000 0.5518
AIRE 11.9(7.6–12.9) 7.6(7.6–7.6) 7.6(7.6–7.6) 0.0027 0.0027 1.0000
Th1/2/9/17 associated genes/Treg associated genes
IL2 9.1(8.4–9.6) 10.0(9.4–10.7) 9.4(9.1–9.7) 0.0014 0.0755 0.0373
TNF 10.8(9.7–11.5) 10.2(10.0–10.5) 9.9(9.7–10.0) 0.2298 0.0163 0.0005
GATA3 7.6(7.6–7.6) 7.7(7.6–8.0) 7.8(7.6–8.3) 0.0000 0.0000 0.7568
IL5 7.6(7.6–12.1) 14.3(14.0–14.9) 13.6(13.4–13.8) 0.0000 0.0000 0.0002
IL13 7.6(7.6–7.6) 10.3(7.6–11.3) 8.9(7.6–10.3) 0.0001 0.0022 0.1755
CCL4 9.5(9.0–10.0) 10.1(10.0–10.3) 10.1(9.8–10.3) 0.0003 0.0051 0.4652
CTLA4 12.0(11.5–12.4) 12.6(12.2–12.7) 12.4(12.1–12.7) 0.0025 0.0091 0.4652
Cytotoxicity genes
GNLY 13.4(12.9–14.2) 15.0(14.4–15.4) 14.6(14.3–15.0) 0.0000 0.0001 0.1595
GZMB 11.7(11.2–12.3) 12.6(12.0–13.0) 12.7(12.2–12.9) 0.0009 0.0010 0.8711
PRF1 7.6(7.6–12.3) 13.9(13.2–14.2) 13.8(13.2–14.2) 0.0000 0.0000 0.8287
Apoptosis/survival
CASP8 12.3(11.9–12.7) 12.8(12.6–13.0) 12.9(12.5–13.1) 0.0002 0.0010 1.0000
BCL2 9.5(8.5–9.9) 10.6(10.1–10.9) 10.2(10.0–11.0) 0.0000 0.0000 0.4171
TNFRSF1A 13.6(13.1–13.8) 13.9(13.7–14.2) 13.8(13.5–14.0) 0.0026 0.0374 0.2235
TNFRSF1B 11.4(10.8–11.8) 11.9(11.7–12.2) 11.5(11.3–11.9) 0.0014 0.2869 0.0094
Myeloid associated genes
CD163 8.9(8.6–9.3) 9.3(9.0–9.6) 9.4(9.3–9.7) 0.0029 0.0000 0.2235
CCL2 7.9(7.6–9.4) 7.6(7.6–8.2) 7.6(7.6–7.6) 0.0410 0.0103 0.3188
CCL5 13.9(13.6–14.1) 14.6(14.3–15.0) 14.5(14.3–14.9) 0.0000 0.0002 0.3577
CCL22 13.9(12.3–15.3) 14.8(14.4–15.5) 13.9(13.8–14.2) 0.0178 0.8854 0.0003
CXCL13 10.8(10.2–11.2) 11.3(11.0–11.4) 11.1(10.7–11.3) 0.0010 0.0837 0.1298
IL12B 7.6(7.6–8.2) 8.6(8.3–9.1) 7.9(7.6–8.6) 0.0000 0.0524 0.0055
IL23A 11.4(11.3–11.7) 9.5(8.4–11.3) 11.3(11.3–11.4) 0.0000 0.0547 0.0009
Pattern recognition receptors
MRC2 7.6(7.6–8.8) 7.6(7.6–7.6) 7.6(7.6–7.6) 0.0007 0.0007 1.0000
NOD2 8.9(8.0–9.5) 8.0(7.6–8.4) 7.7(7.6–8.0) 0.0004 0.0000 0.3677
TLR3 10.1(9.5–10.8) 9.4(9.3–9.8) 10.5(9.8–10.9) 0.0149 0.4760 0.0080
TLR5 13.6(8.8–15.1) 7.6(7.6–8.0) 8.4(7.6–10.7) 0.0000 0.0001 0.0302
TLR9 11.8(7.6–14.2) 15.5(15.1–15.9) 14.9(14.9–15.3) 0.0000 0.0000 0.0063
Inflammasome components
NLRP1 7.6(7.6–9.5) 11.1(10.8–11.6) 11.1(10.7–11.5) 0.0000 0.0000 0.7455
NLRP2 11.1(10.0–12.0) 12.7(11.9–13.4) 11.7(11.6–12.1) 0.0000 0.0082 0.0102
NLRP12 8.4(8.0–8.7) 9.2(9.1–9.5) 9.3(8.9–9.5) 0.0000 0.0000 0.6652
(Continued)
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except 4 host genes (TNF, CCL2, RAB13 and RAB24) that were differentially expressed
between TB cases and TST- also discriminated between TB cases and TST+ (Table 2), suggest-
ing that these biomarkers might be strongly associated with TB disease. Ingenuity pathway net-
work analysis was performed to identify regulatory networks and key genes and biological
pathways: it indicated that the TB associated signature primarily consisted of two networks of
genes identifying immune cell subsets, inflammasome components, pattern recognition recep-
tors and cytotoxicity genes (Fig 1A).
Of the 17 genes that were differentially expressed between TST+ and TST-, 4 genes, includ-
ing CD19, IL23A, TLR3 and TLR5, had significantly lower expression in TST+ compared to
TST-, whereas 13 genes including IL2, TNF, IL5, TNFRSF1B, CCL22, IL12B, TLR9, NLRP2,
NLRP13, FCGR1A, RAB24, BPI and TWIST1, had significantly higher expression (Table 2).
IPA analysis of these differences between TST+ and TST- subjects identified a network cen-
tered around pro-inflammatory cytokines and containing multiple pattern recognition recep-
tors (Fig 1B).
Non-parametric Receiver Operator Characteristic (ROC) curves to determine the discrimi-
natory potential of single genes identified IL7R, CD3E, IL5, NLRP1, PRF1, TLR9, CCR7,
NLRP12, TAGAP, BCL2, TLR5, CCL5, PTPRCv1, FCGR1A, BLR1, GNLY, NLRP2, IL23A,
RAB33A, NCAM1, IL12B, CD4, BPI and CASP8 with Area Under the Curve (AUCs) of 0.99,
0.98, 0.97, 0.96, 0.95, 0.95, 0.92, 0.92, 0.91, 0.91, 0.89, 0.88, 0.87, 0.86, 0.86, 0.85, 0.85, 0.84, 0.84,
0.83, 0.83, 0.81, 0.81 and 0.80 respectively as those genes with the most powerful classifying
potential to discriminate between TB cases and TST+ (Fig 2A). Genes that could best classify
TB patients and TST- were IL7R, PRF1, NLRP1, CD3E, CCR7, FCGR1A, IL5, TLR9, BLR1,
CD19, NLRP12, NOD2, PTPRCv1, GNLY, TLR5, NCAM1 and RAB33A with AUCs of 0.97,
0.94, 0.94, 0.93, 0.93, 0.93, 0.91, 0.89, 0.88, 0.87, 0.87, 0.83, 0.83, 0.81, 0.80, 0.80 and 0.80
Table 2. (Continued)
Gene Symbol TB cases (n = 40) TST+ (n = 20) TST- (n = 20) TB cases vs TST+
P-value
TB cases vs TST-
P-value
TST+ vs TST-
P-value
NLRP13 7.6(7.6–8.9) 8.6(8.1–9.8) 8.1(7.6–8.9) 0.0087 0.4112 0.0490
IFN signalling genes
FCGR1A 11.4(10.7–11.7) 9.4(9.1–10.4) 8.8(8.1–9.3) 0.0000 0.0000 0.0014
Inflammation
TIMP2 14.3(13.5–14.7) 14.6(14.4–14.8) 14.5(14.2–14.7) 0.0170 0.2623 0.1850
Other
AREG 7.6(7.6–12.1) 11.9(11.8–12.3) 12.0(11.5–12.4) 0.0005 0.0004 0.8498
TGFBR2 11.5(11.0–12.0) 11.9(11.7–12.3) 11.7(11.4–12.1) 0.0156 0.3130 0.1595
RAB13 8.2(7.6–8.8) 9.0(7.6–10.0) 9.4(8.4–9.8) 0.0860 0.0011 0.7128
RAB24 11.5(11.1–11.8) 11.2(10.8–11.5) 10.9(10.6–11.1) 0.1735 0.0008 0.0305
RAB33A 7.6(7.6–7.6) 8.3(7.8–8.8) 8.2(7.7–8.6) 0.0000 0.0000 0.6832
TAGAP 12.6(12.1–13.0) 13.5(13.3–13.5) 13.4(13.2–13.6) 0.0000 0.0000 0.7251
BPI 14.5(13.7–15.0) 15.2(14.9–15.4) 14.6(14.5–14.9) 0.0001 0.0704 0.0029
TWIST1 7.6(7.6–7.6) 7.6(7.6–8.0) 7.6(7.6–7.6) 0.0030 0.4739 0.0090
SEC14L1 13.9(13.7–14.3) 14.3(14.1–14.9) 14.2(13.9–14.8) 0.0143 0.0420 0.5162
BLR1 9.4(9.2–10.1) 10.8(10.3–11.1) 10.8(10.5–11.4) 0.0000 0.0000 0.4989
Median (inter quartile range) gene expression values (peak areas normalized for GAPDH and log2-transformed) are shown at baseline and significant differences
between study groups were determined using Kruskal-Wallis H and Wilcoxon Mann-Whitney test. In red, genes are indicated that were more highly expressed in the
test group compared to the reference/control group while blue indicates genes that had lower expression in the test group compared to the reference/control group.
Only genes whose expression level significantly differed between any of the study groups are listed. P-values� 0.05 are indicated in bold.
https://doi.org/10.1371/journal.pone.0226137.t002
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Fig 1. IPA network analysis. Ingenuity Pathway Analysis in HIV-negative individuals of (A) TB-associated genes that were differentially expressed between
TB cases and TST+ individuals as well as between TB cases and TST- individuals at baseline and (B) genes that were differentially expressed between TST+ and
TST- individuals at baseline. Dark blue: T cell associated genes, Light blue: B cell associated genes, Yellow: Cytotoxicity associated genes, Green: Pattern
recognition receptors, Purple: IFN-inducible genes, Pink: Inflammasome components, Orange: NK cell associated genes, Red: Pro-inflammatory cytokines.
https://doi.org/10.1371/journal.pone.0226137.g001
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respectively (Fig 2B). Transcriptomic profiles of those host genes (n = 15) that markedly classi-
fied active TB from both latent TB and healthy controls individuals (AUCs� 0.80) are dis-
played in Fig 3. Genes that could discriminate TST+ from TST- were IL5, CCL22, TNF, IL23A
and FCGR1A with AUCs of 0.84, 0.84, 0.82, 0.81 and 0.80 respectively (Fig 2C). Transcrip-
tomic profiles of these genes that markedly classified latent TB and healthy controls are also
displayed in Fig 3.
Impact of anti-TB treatment (ATT) on the kinetic responses of the
biomarkers associated with active TB
Next, we assessed the effect of ATT treatment on expression of the genes that markedly dis-
criminated between TB cases versus TST+ and TST- controls at baseline. Thus, the gene
expression of these markers in TB patients was measured at six months (6M) of ATT and com-
pared to the baseline value (0M) of the same patients and with that of both control groups
(TST+ and TST-). The expression levels of genes that markedly discriminated between TB
cases versus TST+ and TST- at baseline partially normalized between baseline and 6M in TB
patients following ATT treatment. Interestingly, the expression levels of many genes had not
fully normalized to TST+ or TST- levels at the end of 6M of ATT therapy (Fig 3 & Table 3).
Only the expression of 8 genes, including 4 transcripts which were among those with the most
powerful potential to discriminate between TB disease and TST+ or TST- (PTPRCv1,
FCGR1A, CASP8 and GNLY) (Fig 2), became indistinguishable from those of TST+ and TST-
at the end of 6M ATT therapy (Table 3). However, most of the genes whose expression levels
were not completely normalized yet at 6M did display expression levels that were indistin-
guishable from TST+ or TST- at 18 months follow up (Table 4 & Fig 4).
Different gene networks discriminate TB cases from controls in HIV-
positive and HIV-negative individuals
Out of the 48 genes which were significantly differentially expressed between TB cases and
TST+ subjects in this HIV-negative cohort, only 7 genes (CD4, PTPRCv1, TLR3, TNFRSF1A,
NLRP12, BLR1 and FCGR1A) were significantly different between HIV-positive TB cases and
TST+ individuals in our previous study in the same location [24]. Moreover, the expression of
TNFRSF1A, TLR3 and NLRP12 was significantly higher in TB cases than TST+ controls dur-
ing HIV coinfection, in contrast to the results obtained here in HIV negative individuals. Simi-
larly, only 12 out of the 39 host genes which were significantly differentially expressed between
TB cases and TST- in HIV negative individuals, including FCGR1A, RAB24, CD3E, CD4,
IL7R, PTPRCv1, GNLY, GZMB, TNFRSF1A, CCL5, NLRP12 and BLR1, were also signifi-
cantly different between TB cases and TST- in HIV coinfected individuals in our previous
study [24], and again the expression of TNFRSF1A and NLRP12 was significantly higher in TB
cases than TST- controls during HIV coinfection, in contrast to the results obtained here in
HIV negative individuals. None of the 17 host genes which were significantly differentially
expressed between HIV-negative TST+ and TST- individuals was significantly different in
HIV positive TST+ and TST- individuals in our previous study [24].
Ingenuity Pathway Analysis of the data from the HIV-positive cohort in the previous study
[24] revealed an over-representation of pattern recognition receptors including TLR2 and
TLR4 (Fig 5A) in TB-associated genes which was not seen in the HIV-negative cohort (Fig
Fig 2. Identification of single genes with discriminatory power to classify HIV-negative study groups at baseline (M0).
Receiver operator characteristics (ROC) curves showing the accuracies of individual genes in discriminating (A) TB cases versus
TST+ subjects, (B) TB cases versus TST- subjects and (C) TST+ versus TST- subjects. AUC = Area under the curve.
https://doi.org/10.1371/journal.pone.0226137.g002
Host biomarkers classifying tuberculosis infection and disease status
PLOS ONE | https://doi.org/10.1371/journal.pone.0226137 December 10, 2019 10 / 23
Host biomarkers classifying tuberculosis infection and disease status
PLOS ONE | https://doi.org/10.1371/journal.pone.0226137 December 10, 2019 11 / 23
1A). The comparison of HIV-positive TST+ and TST- individuals revealed a central role for
cytotoxicity and T cell genes (Fig 5B) in contrast to the dominance of pro-inflmmatory cyto-
kines seen in HIV-negative individuals (Fig 1B).
Discussion
Assessing the consistency of previously identified candidate biomarkers and finding additional
candidate genes for diagnosing TB disease and for monitoring treatment responses will be
important for the future direction of TB disease control. Here, we identified gene expression
patterns which could discriminate clinical stages of TB, using a focused gene expression profil-
ing platform, dcRT-MLPA [18], targeting innate and adaptive immune response genes, to ana-
lyze RNA expression levels of 105 pre-selected genes in peripheral blood. The gene expression
of 15 genes with AUCs�0.80 (IL7R, CD3E, IL5, NLRP1, PRF1, TLR9, CCR7, NLRP12, TLR5,
PTPRCv1, FCGR1A, BLR1, GNLY, RAB33A and NCAM1) was strongly associated with TB
disease and these genes indeed play critical roles in the immune response against TB. There
was a clear association between TB disease and low BMI in this cohort: observed gene expres-
sion differences might be related to nutritional status but this is intrinsically linked to disease
profile in TB.
Expression of TLR9, NLRP1, NLPR12, RAB33A and BLR1 was significantly lower in TB
patients compared to TST+ and TST- subjects, in agreement with published data [18,25,26,
27]. Toll-like receptors (TLR) play a critical role in the innate immune response to exogenous
pathogens. Low expression of TLR9 has a critical role in TB incidence and progression, and
this might be associated with combined defects in pro-inflammatory cytokine production such
as IFN-γ recall responses [26]. Low expression of NLRP1 and NLRP12 might be related to a
risk of susceptibility for bacterial diseases, via reduced cleavage of pro-IL-1β and pro-IL-18 to
produce mature isoforms [28], and via avoidance of infected macrophage lysis [29] which con-
tributes to pathology in TB. Rab33A is a novel CD8+ T cell factor and the expression may
involved in susceptibility to TB disease [27].
The observed lower expression of T cell associated genes (e.g. IL7R, CD3E, CCR7 and
PTPRCv1) in TB patients has been shown previously [21,30] and might be associated with
reactivation of infection and migration of cells to the site of infection [31]. Similarly, lower
expression of other immune subset genes (such as NK marker NCAM1) in blood in TB
patients may also relate to migration of lymphocytes or natural killer cells from the peripheral
blood to the site of infection [32]. Furthermore, GNLY and PRF1 expression levels were also
significantly lower in TB patients compared to TST+ and TST- individuals, which is consistent
with published data [33,34] and might be explained by rapid consumption of both perforin
and granulysin during active disease due to an ongoing effector immune response, or due to
migration of the T cell subset responsible for its production [35].
FCGR1A and TLR5 were also found to be differentially expressed between TB cases and
TST+ or TST- individuals, in agreement with published data [36,37,38,39]. However, these
genes were higher expressed in TB patients compared to controls and were found to constitute
the best discriminatory power between TB cases versus both TST+ and TST- controls.
FCGR1A is an essential component of interferon signalling and plays a central role in endocy-
tosis, phagocytosis, antibody-dependent cellular toxicity, cytokine release, and superoxide
Fig 3. Gene expression profiles of signature genes. Median gene expression levels (peak areas normalized to GAPDH and log2-transformed) of
the indicated genes are shown as box-and-whisker plots (5–95 percentiles). Significant differences among the groups and between study groups
were determined using Kruskal-Wallis H test and Wilcoxon Mann-Whitney test respectively. Shown are individual genes that were found to have
the best discriminatory power (AUCs� 0.80) to distinguish between active TB cases (TB) versus latently infected (TST+) and uninfected (TST-)
controls in HIV-negative subjects. (� = P-value�0.05, �� = P-value�0.01, ��� = P-value�0.001, ���� = P-value�0.0001).
https://doi.org/10.1371/journal.pone.0226137.g003
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Table 3. Kinetic profiling of the response to TB treatment at 6M of ATT in active TB patients.
Gene Symbol TB cases (0M) TB cases (6M) TST+ (0M) TST- (0M) TB cases (6M) vs
TB cases (M0)
TB cases (6M) vs
TST+ (M0)
TB cases (6M) vs
TST- (M0)
Immune cell subset markers
CD19 7.6(7.6–7.6) 9.7 (9.4–9.9) 7.7(7.6–8.1) 8.2(7.8–8.6) 0.0000 0.0205 0.7626
NCAM1 8.4(7.6–8.7) 8.4 (8.1–9.0) 9.4(8.8–9.9) 9.3(8.7–9.6) 0.5832 0.0005 0.0045
T cell subset markers
CD3E 12.5(11.3–13.0) 13.4(13.0–14.1) 14.2(13.8–14.6) 14.1(13.7–14.3) 0.0000 0.0015 0.0145
CD4 12.0(11.4–12.5) 11.7(11.2–12.6) 12.8(12.4–13.3) 12.3(12.1–12.9) 0.3886 0.0000 0.0068
CD8A 12.7(12.3–13.0) 14.1(13.9–14.4) 13.0(12.8–13.4) 13.1(12.9–13.2) 0.0000 0.0000 0.0000
CCR7 12.8(12.2–13.4) 13.2(12.9–13.7) 14.7(14.1–15.0) 14.2(14.0–14.4) 0.0684 0.0000 0.0000
IL7R 12.1(11.7–13.0) 13.4 (12.6–13.8) 14.1(13.7–14.5) 14.1(13.8–14.4) 0.0001 0.0000 0.0001
PTPRCv1 10.7(10.2–11.3) 11.7 (11.1–12.1) 12.1(11.5–12.3) 12.0(11.3–12.2) 0.0008 0.0803 0.3470
AIRE 7.6(7.6–12.9) 12.8(12.4 to 13.3) 7.6(7.6–7.6) 7.6(7.6–7.6) 0.0014 0.0000 0.0000
Th1/2/9/17 associated genes/Treg associated genes
IL2 9.1(8.4–9.6) 9.6(9.2–10.3) 10.0(9.4–10.7) 9.4(9.1–9.7) 0.0135 0.2009 0.3470
TNF 10.8(9.7–11.5) 12.3 (11.9–12.6) 10.2(10.0–10.5) 9.9(9.7–10.0) 0.0000 0.0000 0.0001
GATA3 7.6(7.6–7.6) 7.6 (7.6–7.7) 7.7(7.6–8.0) 7.8(7.6–8.3) 0.0841 0.0448 0.0346
IL5 7.6(7.6–12.1) 7.6 (7.6–7.6) 14.3(14.0–14.9) 13.6(13.4–13.8) 0.0001 0.0000 0.0000
IL13 7.6(7.6–7.6) 7.6 (7.6–7.6) 10.3(7.6–11.3) 8.9(7.6–10.3) 0.0048 0.0000 0.0000
CCL4 9.5(9.0–10.0) 10.4 (10.1–11.0) 10.1(10.0–10.3) 10.1(9.8–10.3) 0.0000 0.0089 0.0016
CTLA4 12.0(11.5–12.4) 11.8 (11.6–12.4) 12.6(12.2–12.7) 12.4(12.1–12.7) 0.4653 0.0023 0.0049
Cytotoxicity genes
GNLY 13.4(12.9–14.2) 14.5 (13.9–15.2) 15.0(14.4–15.4) 14.6(14.3–15.0) 0.0011 0.0941 0.5225
GZMB 11.7(11.2–12.3) 12.2 (11.9–12.6) 12.6(12.0–13.0) 12.7(12.2–12.9) 0.0068 0.2886 0.1896
PRF1 7.6(7.6–12.3) 7.6 (7.6–7.6) 13.9(13.2–14.2) 13.8(13.2–14.2) 0.0001 0.0000 0.0000
Apoptosis/survival
CASP8 12.3(11.9–12.7) 12.9 (12.5–13.2) 12.8(12.6–13.0) 12.9(12.5–13.1) 0.0033 0.9850 0.9850
BCL2 9.5(8.5–9.9) 10.1(9.6–10.4) 10.6(10.1–10.9) 10.2(10.0–11.0) 0.0002 0.0060 0.1185
TNFRSF1A 13.6(13.1–13.8) 13.5 (13.3–13.8) 13.9(13.7–14.2) 13.8(13.5–14.0) 0.7096 0.0036 0.0462
TNFRSF1B 11.4(10.8–11.8) 12.5 (12.1–12.8) 11.9(11.7–12.2) 11.5(11.3–11.9) 0.0002 0.0048 1.0000
Myeloid associated genes
CD163 8.9(8.6–9.3) 7.6 (7.6–8.1) 9.3(9.0–9.6) 9.4(9.3–9.7) 0.0000 0.0000 0.0000
CCL2 7.9(7.6–9.4) 8.1 (7.6–9.2) 7.6(7.6–8.2) 7.6(7.6–7.6) 0.8752 0.0324 0.0048
CCL5 13.9(13.6–14.1) 14.0 (13.6–14.3) 14.6(14.3–15.0) 14.5(14.3–14.9) 0.7989 0.0002 0.0019
CCL22 13.9(12.3–15.3) 13.4 (12.2–14.2) 14.8(14.4–15.5) 13.9(13.8–14.2) 0.1959 0.0000 0.0575
CXCL13 10.8(10.2–11.2) 11.4 (10.9–11.9) 11.3(11.0–11.4) 11.1(10.7–11.3) 0.0327 0.3374 0.0360
IL12B 7.6(7.6–8.2) 7.6 (7.6–7.9) 8.6(8.3–9.1) 7.9(7.6–8.6) 0.8771 0.0000 0.0248
IL23A 11.4(11.3–11.7) 11.5 (11.4–11.7) 9.5(8.4–11.3) 11.3(11.3–11.4) 0.0121 0.0000 0.0001
Pattern recognition receptors
MRC2 7.6(7.6–8.8) 9.6 (9.0–10.3) 7.6(7.6–7.6) 7.6(7.6–7.6) 0.0000 0.0000 0.0000
NOD2 8.9(8.0–9.5) 9.5 (9.1–9.8) 8.0(7.6–8.4) 7.7(7.6–8.0) 0.0415 0.0000 0.0000
TLR3 10.1(9.5–10.8) 10.0 (9.5–10.6) 9.4(9.3–9.8) 10.5(9.8–10.9) 0.9375 0.0124 0.1696
TLR5 13.6(8.8–15.1) 14.9 (14.1–15.3) 7.6(7.6–8.0) 8.4(7.6–10.7) 0.0460 0.0000 0.0000
TLR9 11.8(7.6–14.2) 7.6 (7.6–7.6) 15.5(15.1–15.9) 14.9(14.9–15.3) 0.0007 0.0000 0.0001
Inflammasome components
NLRP1 7.6(7.6–9.5) 7.6 (7.6–7.6) 11.1(10.8–11.6) 11.1(10.7–11.5) 0.0001 0.0000 0.0001
NLRP2 11.1(10.0–12.0) 11.7 (11.4–12.2) 12.7(11.9–13.4) 11.7(11.6–12.1) 0.0132 0.0007 0.6248
NLRP12 8.4(8.0–8.7) 8.2 (7.9–8.5) 9.2(9.1–9.5) 9.3(8.9–9.5) 0.0900 0.0000 0.0001
(Continued)
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generation [40] but may also participate in TB pathogenesis. In contrast, TLR5 is expressed in
myeloid cells during TB infection and its role may associate with an imbalance in Th1 and Th2
cells by increasing the expression of IL-4 [41].
We also assessed the expression levels of host genes in response to ATT. We showed that
expression levels of a subset of genes that markedly discriminated between TB cases versus
TST+ and/or TST- controls at baseline were normalized in ATT treated TB patients at 6
months. However, in contrast to most previous studies in which normalization was completed
between 2 and 6 months of treatment [42,43], the majority of the genes in our study were only
fully normalized at the 18 months follow-up time point. Treatment-response transcriptomic
signatures can significantly change already within 1 week of treatment [44], and continue to
change until the end of ATT treatment at 6 months [18,45] and even after treatment is com-
pleted [11,46]. The expression of only a small number of genes, including PTPRCv1, FCGR1A,
GZMB, CASP8 and GNLY, fully returned to the expression levels observed in TST+ and TST-
subjects after the full 6 months of treatment in this study. Differential expression of gene pro-
files in TB patients during 6 months anti-TB chemotherapy compared to baseline has previ-
ously been reported [42,43,47] and correlated with a clearance of actively dividing bacilli load
[44]. However, TB cases with clinically curative treatment at the end of 6 months therapy may
not have completely cleared the infection yet, and may not have reached the end of the disease
pathology resolution process due to the presence of few remaining viable Mtb, with the poten-
tial to elicit a host response [48] as well as ongoing immunopathology in sterilized lesions.
There were some notable differences in discriminating TB cases from controls using the
expression of immune-related genes amongst HIV-positive [24] and -negative individuals
Table 3. (Continued)
Gene Symbol TB cases (0M) TB cases (6M) TST+ (0M) TST- (0M) TB cases (6M) vs
TB cases (M0)
TB cases (6M) vs
TST+ (M0)
TB cases (6M) vs
TST- (M0)
NLRP13 7.6(7.6–8.9) 7.7 (7.6–8.4) 8.6(8.1–9.8) 8.1(7.6–8.9) 0.2677 0.0006 0.2327
IFN signalling genes
FCGR1A 11.4(10.7–11.7) 9.6 (8.2–10.6) 9.4(9.1–10.4) 8.8(8.1–9.3) 0.0004 0.7777 0.0546
Inflammation
TIMP2 14.3(13.5–14.7) 14.2 (13.9–14.5) 14.6(14.4–14.8) 14.5(14.2–14.7) 0.3779 0.0020 0.0803
Other
AREG 7.6(7.6–12.1) 7.6 (7.6–7.6) 11.9(11.8–12.3) 12.0(11.5–12.4) 0.0001 0.0000 0.0001
TGFBR2 11.5(11.0–12.0) 12.2 (11.6–12.5) 11.9(11.7–12.3) 11.7(11.4–12.1) 0.0002 0.3666 0.0653
RAB13 8.2(7.6–8.8) 9.3 (8.9–9.9) 9.0(7.6–10.0) 9.4(8.4–9.8) 0.0001 0.4554 0.6718
RAB24 11.5(11.1–11.8) 11.3 (10.9–11.7) 11.2(10.8–11.5) 10.9(10.6–11.1) 0.1364 0.8656 0.0187
RAB33A 7.6(7.6–7.6) 7.6 (7.6–8.3) 8.3(7.8–8.8) 8.2(7.7–8.6) 0.0577 0.0059 0.0320
TAGAP 12.6(12.1–13.0) 12.5 (12.1–12.9) 13.5(13.3–13.5) 13.4(13.2–13.6) 0.1763 0.0000 0.0001
BPI 14.5(13.7–15.0) 13.6 (13.2–14.2) 15.2(14.9–15.4) 14.6(14.5–14.9) 0.0311 0.0000 0.0001
TWIST1 7.6(7.6–7.6) 7.6 (7.6–7.6) 7.6(7.6–8.0) 7.6(7.6–7.6) 0.9815 0.0092 0.5724
SEC14L1 13.9(13.7–14.3) 14.0 (13.5–14.5) 14.3(14.1–14.9) 14.2(13.9–14.8) 0.9844 0.0252 0.0385
BLR1 9.4(9.2–10.1) 10.5 (10.1–11.0) 10.8(10.3–11.1) 10.8(10.5–11.4) 0.0002 0.2076 0.0368
Median (inter quartile range) gene expression values (peak areas normalized for GAPDH and log2-transformed) are shown. Significant differences between active TB
patients at baseline (0M) and 6 months following ATT treatment initiation (6M) were determined using Wilcoxon signed-rank test. Significant differences between
active TB at the 6M and TST+ or TST- at the 0M time point was determined using Wilcoxon Mann-Whitney test. In red, genes are indicated that were more highly
expressed in the test group compared to the reference/control group whereas in blue genes are indicated that had lower expression in the test group compared to the
reference/control group. Genes listed in this table were differentially expressed between any of the study groups at baseline (0M) (Table 2). P-values� 0.05 are indicated
in bold.
https://doi.org/10.1371/journal.pone.0226137.t003
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Table 4. Kinetic profiling of the response to TB treatment after completed ATT in active TB patients (18M).
Gene Symbol TB cases (0M) TB cases (18M) TST+ (0M) TST- (0M) TB cases (18M)
vs
TB cases (0M)
TB cases (18M)
vs
TST+ (0M)
TB cases (18M)
vs
TST- (0M)
Immune cell subset markers
CD19 7.6(7.6–7.6) 8.7 (8.3–9.0) 7.7(7.6–8.1) 8.2(7.8–8.6) 0.0001 0.0022 0.0581
NCAM1 8.4(7.6–8.7) 9.3(8.7–10.0) 9.4(8.8–9.9) 9.3(8.7–9.6) 0.0009 0.9709 0.6968
T cell subset markers
CD3E 12.5(11.3–13.0) 14.0(13.7–14.5) 14.2(13.8–14.6) 14.1(13.7–14.3) 0.0000 0.4203 0.9198
CD4 12.0(11.4–12.5) 12.8(12.6–13.2) 12.8(12.4–13.3) 12.3(12.1–12.9) 0.0042 0.6091 0.0302
CD8A 12.7(12.3–13.0) 14.0(13.7–14.3) 13.0(12.8–13.4) 13.1(12.9–13.2) 0.0000 0.0000 0.0000
CCR7 12.8(12.2–13.4) 13.6(13.2–14.0) 14.7(14.1–15.0) 14.2(14.0–14.4) 0.0012 0.0032 0.0052
IL7R 12.1(11.7–13.0) 13.7(13.2–14.2) 14.1(13.7–14.5) 14.1(13.8–14.4) 0.0000 0.0051 0.0130
PTPRCv1 10.7(10.2–11.3) 13.1(12.5–13.5) 12.1(11.5–12.3) 12.0(11.3–12.2) 0.0000 0.0000 0.0000
AIRE 7.6(7.6–12.9) 8.3(7.64–9.1) 7.6(7.6–7.6) 7.6(7.6–7.6) 0.0388 0.0000 0.0000
Th1/2/9/17 associated genes/Treg associated genes
IL2 9.1(8.4–9.6) 10.3(9.5–11.0) 10.0(9.4–10.7) 9.4(9.1–9.7) 0.0009 0.5921 0.0235
TNF 10.8(9.7–11.5) 10.0(12.3–14.4) 10.2(10.0–10.5) 9.9(9.7–10.0) 0.6926 0.0027 0.0000
GATA3 7.6(7.6–7.6) 8.1(7.64–8.3) 7.7(7.6–8.0) 7.8(7.6–8.3) 0.0001 0.0873 0.2960
IL5 7.6(7.6–12.1) 14.0(12.3–14.4) 14.3(14.0–14.9) 13.6(13.4–13.8) 0.0000 0.0251 0.3181
IL13 7.6(7.6–7.6) 7.64(7.64–9.0) 10.3(7.6–11.3) 8.9(7.6–10.3) 0.2937 0.0118 0.0932
CCL4 9.5(9.0–10.0) 10.7(10.3–11.3) 10.1(10.0–10.3) 10.1(9.8–10.3) 0.0001 0.0020 0.0003
CTLA4 12.0(11.5–12.4) 13.3(13.1–13.6) 12.6(12.2–12.7) 12.4(12.1–12.7) 0.0000 0.0000 0.0000
Cytotoxicity genes
GNLY 13.4(12.9–14.2) 14.9(14.0–11.3) 15.0(14.4–15.4) 14.6(14.3–15.0) 0.0003 0.6091 0.3301
GZMB 11.7(11.2–12.3) 12.5(12.1–13.0) 12.6(12.0–13.0) 12.7(12.2–12.9) 0.0029 0.7332 0.6789
PRF1 7.6(7.6–12.3) 13.6(10.3–11.3) 13.9(13.2–14.2) 13.8(13.2–14.2) 0.0000 0.3676 0.5590
Apoptosis/survival
CASP8 12.3(11.9–12.7) 13.3(13.0–13.5) 12.8(12.6–13.0) 12.9(12.5–13.1) 0.0000 0.0038 0.0030
BCL2 9.5(8.5–9.9) 10.4(9.9–10.7) 10.6(10.1–10.9) 10.2(10.0–11.0) 0.0001 0.3941 0.8171
TNFRSF1A 13.6(13.1–13.8) 14.1(13.9–14.3) 13.9(13.7–14.2) 13.8(13.5–14.0) 0.0011 0.2172 0.0136
TNFRSF1B 11.4(10.8–11.8) 12.8(12.6–13.2) 11.9(11.7–12.2) 11.5(11.3–11.9) 0.0002 0.0000 0.0000
Myeloid associated genes
CD163 8.9(8.6–9.3) 8.1(7.8–8.4) 9.3(9.0–9.6) 9.4(9.3–9.7) 0.0262 0.0000 0.0000
CCL2 7.9(7.6–9.4) 9.5(8.8–10.0) 7.6(7.6–8.2) 7.6(7.6–7.6) 0.0010 0.0000 0.0000
CCL5 13.9(13.6–14.1) 14.9(14.3–15.1) 14.6(14.3–15.0) 14.5(14.3–14.9) 0.0000 0.4504 0.1375
CCL22 13.9(12.3–15.3) 14.8(13.9–15.2) 14.8(14.4–15.5) 13.9(13.8–14.2) 0.1808 0.3181 0.0221
CXCL13 10.8(10.2–11.2) 12.8(12.5–13.3) 11.3(11.0–11.4) 11.1(10.7–11.3) 0.0000 0.0000 0.0000
IL12B 7.6(7.6–8.2) 7.64(7.64–7.9) 8.6(8.3–9.1) 7.9(7.6–8.6) 0.9373 0.0007 0.0793
IL23A 11.4(11.3–11.7) 11.5(9.9–11.6) 9.5(8.4–11.3) 11.3(11.3–11.4) 0.9273 0.0013 0.2054
Pattern recognition receptors
MRC2 7.6(7.6–8.8) 8.6(8.2–10.1) 7.6(7.6–7.6) 7.6(7.6–7.6) 0.0006 0.0000 0.0000
NOD2 8.9(8.0–9.5) 9.4(9.2–10.2) 8.0(7.6–8.4) 7.7(7.6–8.0) 0.0074 0.0000 0.0000
TLR3 10.1(9.5–10.8) 9.2(8.5–9.6) 9.4(9.3–9.8) 10.5(9.8–10.9) 0.0014 0.0194 0.0004
TLR5 13.6(8.8–15.1) 14.8(14.3–15.3) 7.6(7.6–8.0) 8.4(7.6–10.7) 0.1070 0.0000 0.0000
TLR9 11.8(7.6–14.2) 15.7(14.9–16.1) 15.5(15.1–15.9) 14.9(14.9–15.3) 0.0000 0.6436 0.0575
Inflammasome components
NLRP1 7.6(7.6–9.5) 9.4(8.7–9.7) 11.1(10.8–11.6) 11.1(10.7–11.5) 0.0703 0.0000 0.0000
NLRP2 11.1(10.0–12.0) 12.9(12.6–13.2) 12.7(11.9–13.4) 11.7(11.6–12.1) 0.0000 0.3423 0.0000
NLRP12 8.4(8.0–8.7) 9.1(8.4–9.3) 9.2(9.1–9.5) 9.3(8.9–9.5) 0.0065 0.0543 0.1648
(Continued)
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(this study). The discriminatory potential of genes identified in HIV-negative individuals
using ROC included immune cell markers (NCAM1), T cell associated genes (IL7R, CD3E,
CCR7, PTPRCv1), T helper type 2 associated genes (IL5), cytotoxicity genes (GNLY and
PRF1), pattern recognition receptors (TLR5 and TLR9), inflamasome components (NLRP1
and NLRP12), IFN signalling genes (FCGR1A), GTPase activating genes (RAB33A) and G-
protein couple receptors (BLR1) (Fig 2A and 2B). With the exception of FCGR1A, all of these
genes did not have discriminatory potential amongst HIV-positive individuals using ROC
cutoff� 0.80 [24]. Pattern recognition receptors, including TLR2 and TLR4, were over-repre-
sented in network analysis of TB-associated genes in HIV-positive individuals (Fig 5A) which
was not the case in HIV-negative individuals (Fig 1A), revealing fundamental differences in
biological response and biomarker expression in these cohorts. In previous studies, TB patients
without HIV infection showed no difference in TLR2 and TLR4 expression in monocytes
compared to healthy donors [49] but TLR2 and TLR4 are most strongly up-regulated in mDCs
of TB patients coinfected with HIV [50] consistent with the findings in this report. Using ROC
cutoff� 0.80, the expression of FCGR1A was the only marker consistently identfied in both
HIV-positive and -negative individuals which is consistent with a previous report by Suther-
land et al [30]. The dominance of pro-inflammatory cytokines seen in HIV-negative LTBI may
be related to activation of T cells [51] which may contribute to containment of Mtb infection.
In contrast, low expression of cytotoxicity genes and T cell-associated genes observed in HIV-
positive LTBI may reflect enhanced recruitment of T cells to the site of Mtb infection[52], or
Table 4. (Continued)
Gene Symbol TB cases (0M) TB cases (18M) TST+ (0M) TST- (0M) TB cases (18M)
vs
TB cases (0M)
TB cases (18M)
vs
TST+ (0M)
TB cases (18M)
vs
TST- (0M)
NLRP13 7.6(7.6–8.9) 8.7(7.64–9.5) 8.6(8.1–9.8) 8.1(7.6–8.9) 0.8900 0.6429 0.2560
IFN signalling genes
FCGR1A 11.4(10.7–11.7) 10.3(7.64–11.1) 9.4(9.1–10.4) 8.8(8.1–9.3) 0.0051 0.4494 0.0504
Inflammation
TIMP2 14.3(13.5–14.7) 14.6(14.4–14.9) 14.6(14.4–14.8) 14.5(14.2–14.7) 0.1361 0.8076 0.0883
Other
AREG 7.6(7.6–12.1) 10.8(10.7–11.3) 11.9(11.8–12.3) 12.0(11.5–12.4) 0.6157 0.0000 0.0001
TGFBR2 11.5(11.0–12.0) 12.9(12.1–13.1) 11.9(11.7–12.3) 11.7(11.4–12.1) 0.0000 0.0011 0.0001
RAB13 8.2(7.6–8.8) 9.9(9.7–10.3) 9.0(7.6–10.0) 9.4(8.4–9.8) 0.0000 0.0029 0.0010
RAB24 11.5(11.1–11.8) 11.6(11.3–12.0) 11.2(10.8–11.5) 10.9(10.6–11.1) 0.1997 0.0118 0.0000
RAB33A 7.6(7.6–7.6) 7.64(7.64–7.74) 8.3(7.8–8.8) 8.2(7.7–8.6) 0.3569 0.0015 0.0034
TAGAP 12.6(12.1–13.0) 13.8(13.5–14.3) 13.5(13.3–13.5) 13.4(13.2–13.6) 0.0001 0.0007 0.0007
BPI 14.5(13.7–15.0) 14.8(13.7–15.1) 15.2(14.9–15.4) 14.6(14.5–14.9) 0.1808 0.0041 0.8838
TWIST1 7.6(7.6–7.6) 7.6(7.6–7.6) 7.6(7.6–8.0) 7.6(7.6–7.6) 0.3173 0.0053 1.0000
SEC14L1 13.9(13.7–14.3) 14.5(14.2–15.0) 14.3(14.1–14.9) 14.2(13.9–14.8) 0.0009 0.4217 0.1375
BLR1 9.4(9.2–10.1) 10.7(10.5–11.1) 10.8(10.3–11.1) 10.8(10.5–11.4) 0.0007 0.9612 0.8265
Median (inter quartile range) gene expression values (peak areas normalized for GAPDH and log2-transformed) are shown. Significant differences between active TB
patients at 18 months following ATT treatment initiation (18M) and baseline (0M) were determined using Wilcoxon signed-rank test. Significant differences between
active TB at the 18M and TST+ or TST- at the 0M time point was determined using Wilcoxon Mann-Whitney test. In red genes are indicated that were more highly
expressed in the test group compared to the reference/control group whereas in blue genes are indicated that had lower expression in the test group compared to the
reference/control group. Genes listed in this table were differentially expressed between any of the study groups at baseline (0M) (Table 2). P-values� 0.05 are indicated
in bold.
https://doi.org/10.1371/journal.pone.0226137.t004
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Fig 4. Kinetics of gene expression profiles in response to ATT treatment. Median gene expression levels (peak areas normalized to GAPDH and log2-transformed)
and standard deviations are shown of the indicated genes at baseline (M0), 6 months (6M) and 18 months (18M) after anti-TB treatment (ATT) of HIV-negative
subjects.
https://doi.org/10.1371/journal.pone.0226137.g004
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deletion of the activated T cells [53], which may contribute to HIV disease progression and
exacerbate the HIV epidemic.
There were also notable differences between this report and a previous report in the context
of Ethiopia. While only 9 of 45 host genes genes measured by Mihret et al. had significantly
different expression between active TB cases and household contacts [21], 21 out of these 45
host genes had significantly differencial expression in TB cases compared to both TST+ and
TST- subjects in our study. The expression of FCGR1A and IL7R were the only TB-associated
markers that were consistently differentially expressed between TB patients and control groups
in our study compared to the previous study in the context of Ethiopia and this may be attrib-
utable to the selection criteria for the control groups [30] which consisted of household con-
tacts in Mihret et al. and daily laborers in our study, or may reflects huge genetic heterogeneity
amongst the Ethiopian population. Moreover, 5 out of 45 host genes measured by Mihret et al.
[21] showed differential expression between latent TB infected and uninfected individuals,
whereas 7 of the 45 host genes was differentially expressed between latent TB infected and
uninfected individuals in our study. However, there was no overlap in the genes discriminating
between TST+ and TST- individuals in both studies.
In conclusion, the expression levels of 15 host genes (IL7R, CD3E, IL5, NLRP1, PRF1,
TLR9, CCR7, NLRP12, TLR5, PTPRCv1, FCGR1A, BLR1, GNLY, RAB33A and NCAM1) in
peripheral blood can discriminate active TB disease from latent TB infection and uninfected
controls in an HIV-negative cohort. However, almost all these markers, except for FCGR1A,
can not discriminate between active and latent TB in TB-HIV co-infected subjects. Our data
also show that complex gene expression signatures are required to fully measure changes in
blood transcriptomes during and after successful ATT, such that a combination including
those which resolve completely during the 6-months treatment phase of therapy (PTPRCv1,
FCGR1A, GZMB, CASP8 and GNLY) and those which only fully return to normal levels dur-
ing the post-treatment resolution phase, might be required to fully characterise drug-induced
relapse-free cure. Further research is needed to completely charaterise the optimal complex
signature in different populations and larger study populations.
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